Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology

INTRODUCTION: Pyroglutamate‐modified amyloid β (Aβ(pE3)) could be a biomarker for Aβ plaque pathology in the brain. An ultra‐high‐sensitive assay is needed for detecting Aβ(pE3‐40). METHODS: Immunomagnetic reduction was used for quantification of Aβ(pE3‐40) in plasma from 46 participants. The concen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Pei‐Ning, Lin, Kun‐Ju, Liu, Huei‐Chun, Andreasson, Ulf, Blennow, Kaj, Zetterberg, Henrik, Yang, Shieh‐Yueh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Blood‐based Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191392/
https://www.ncbi.nlm.nih.gov/pubmed/32363230
http://dx.doi.org/10.1002/dad2.12029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191392/
https://www.ncbi.nlm.nih.gov/pubmed/32363230
http://dx.doi.org/10.1002/dad2.12029

Ejemplares similares